Skip to main content
Top
Published in: Arthritis Research & Therapy 1/2006

Open Access 01-02-2005 | Research article

Differential direct effects of cyclo-oxygenase-1/2 inhibition on proteoglycan turnover of human osteoarthritic cartilage: an in vitrostudy

Authors: Simon C Mastbergen, Nathalie WD Jansen, Johannes WJ Bijlsma, Floris PJG Lafeber

Published in: Arthritis Research & Therapy | Issue 1/2006

Login to get access

Abstract

Treatment of osteoarthritis (OA) with nonsteroidal anti-inflammatory drugs (NSAIDs) diminishes inflammation along with mediators of cartilage destruction. However, NSAIDs may exert adverse direct effects on cartilage, particularly if treatment is prolonged. We therefore compared the direct effects of indomethacin, naproxen, aceclofenac and celecoxib on matrix turnover in human OA cartilage tissue. Human clinically defined OA cartilage from five different donors was exposed for 7 days in culture to indomethacin, naproxen, aceclofenac and celecoxib – agents chosen based on their cyclo-oxygenase (COX)-2 selectivity. As a control, SC-560 (a selective COX-1 inhibitor) was used. Changes in cartilage proteoglycan turnover and prostaglandin E2 production were determined. OA cartilage exhibited characteristic proteoglycan turnover. Indomethacin further inhibited proteoglycan synthesis; no significant effect of indomethacin on proteoglycan release was found, and proteoglycan content tended to decrease. Naproxen treatment was not associated with changes in any parameter. In contrast, aceclofenac and, prominently, celecoxib had beneficial effects on OA cartilage. Both were associated with increased proteoglycan synthesis and normalized release. Importantly, both NSAIDs improved proteoglycan content. Inhibition of prostaglandin E2 production indirectly showed that all NSAIDs inhibited COX, with the more COX-2 specific agents having more pronounced effects. Selective COX-1 inhibition resulted in adverse effects on all parameters, and prostaglandin E2 production was only mildly inhibited. NSAIDs with low COX-2/COX-1 selectivity exhibit adverse direct effects on OA cartilage, whereas high COX-2/COX-1 selective NSAIDs did not show such effects and might even have cartilage reparative properties.
Appendix
Available only for authorised users
Literature
1.
go back to reference Hungin AP, Kean WF: Nonsteroidal anti-inflammatory drugs: overused or underused in osteoarthritis?. Am J Med. 2001, 110: 8S-11S. 10.1016/S0002-9343(00)00628-8.CrossRefPubMed Hungin AP, Kean WF: Nonsteroidal anti-inflammatory drugs: overused or underused in osteoarthritis?. Am J Med. 2001, 110: 8S-11S. 10.1016/S0002-9343(00)00628-8.CrossRefPubMed
2.
go back to reference Dieppe PA, Lohmander LS: Pathogenesis and management of pain in osteoarthritis. Lancet. 2005, 365: 965-973. 10.1016/S0140-6736(05)71086-2.CrossRefPubMed Dieppe PA, Lohmander LS: Pathogenesis and management of pain in osteoarthritis. Lancet. 2005, 365: 965-973. 10.1016/S0140-6736(05)71086-2.CrossRefPubMed
3.
go back to reference Goldring MB: The role of the chondrocyte in osteoarthritis. Arthritis Rheum. 2000, 43: 1916-1926. 10.1002/1529-0131(200009)43:9<1916::AID-ANR2>3.0.CO;2-I.CrossRefPubMed Goldring MB: The role of the chondrocyte in osteoarthritis. Arthritis Rheum. 2000, 43: 1916-1926. 10.1002/1529-0131(200009)43:9<1916::AID-ANR2>3.0.CO;2-I.CrossRefPubMed
4.
go back to reference Lazzaroni M, Bianchi Porro G: Gastrointestinal side-effects of traditional non-steroidal anti-inflammatory drugs and new formulations. Aliment Pharmacol Ther. 2004, 20 Suppl 2: 48-58. 10.1111/j.1365-2036.2004.02037.x.CrossRefPubMed Lazzaroni M, Bianchi Porro G: Gastrointestinal side-effects of traditional non-steroidal anti-inflammatory drugs and new formulations. Aliment Pharmacol Ther. 2004, 20 Suppl 2: 48-58. 10.1111/j.1365-2036.2004.02037.x.CrossRefPubMed
5.
go back to reference Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, et al: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 2000, 343: 1520-1528. 10.1056/NEJM200011233432103.CrossRefPubMed Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, et al: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 2000, 343: 1520-1528. 10.1056/NEJM200011233432103.CrossRefPubMed
6.
go back to reference Farkouh ME, Kirshner H, Harrington RA, Ruland S, Verheugt FW, Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, et al: Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet. 2004, 364: 675-684. 10.1016/S0140-6736(04)16894-3.CrossRefPubMed Farkouh ME, Kirshner H, Harrington RA, Ruland S, Verheugt FW, Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, et al: Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet. 2004, 364: 675-684. 10.1016/S0140-6736(04)16894-3.CrossRefPubMed
7.
go back to reference Howard PA, Delafontaine P: Nonsteroidal anti-Inflammatory drugs and cardiovascular risk. J Am Coll Cardiol. 2004, 43: 519-525. 10.1016/j.jacc.2003.09.043.CrossRefPubMed Howard PA, Delafontaine P: Nonsteroidal anti-Inflammatory drugs and cardiovascular risk. J Am Coll Cardiol. 2004, 43: 519-525. 10.1016/j.jacc.2003.09.043.CrossRefPubMed
8.
go back to reference Blot L, Marcelis A, Devogelaer JP, Manicourt DH: Effects of diclofenac, aceclofenac and meloxicam on the metabolism of proteoglycans and hyaluronan in osteoarthritic human cartilage. Br J Pharmacol. 2000, 131: 1413-1421. 10.1038/sj.bjp.0703710.PubMedCentralCrossRefPubMed Blot L, Marcelis A, Devogelaer JP, Manicourt DH: Effects of diclofenac, aceclofenac and meloxicam on the metabolism of proteoglycans and hyaluronan in osteoarthritic human cartilage. Br J Pharmacol. 2000, 131: 1413-1421. 10.1038/sj.bjp.0703710.PubMedCentralCrossRefPubMed
9.
go back to reference Ding C: Do NSAIDs affect the progression of osteoarthritis?. Inflammation. 2002, 26: 139-142. 10.1023/A:1015504632021.CrossRefPubMed Ding C: Do NSAIDs affect the progression of osteoarthritis?. Inflammation. 2002, 26: 139-142. 10.1023/A:1015504632021.CrossRefPubMed
10.
go back to reference Dingle JT: The effect of nonsteroidal antiinflammatory drugs on human articular cartilage glycosaminoglycan synthesis. Osteoarthritis Cartilage. 1999, 7: 313-314. 10.1053/joca.1998.0176.CrossRefPubMed Dingle JT: The effect of nonsteroidal antiinflammatory drugs on human articular cartilage glycosaminoglycan synthesis. Osteoarthritis Cartilage. 1999, 7: 313-314. 10.1053/joca.1998.0176.CrossRefPubMed
11.
go back to reference Henroitin Y, Reginster JY: In-vitro differences among nonsteroidal antiinflammatory drugs in their activities related to osteoarthritis pathophysiology. Osteoarthritis Cartilage. 1999, 7: 355-357. 10.1053/joca.1998.0197.CrossRefPubMed Henroitin Y, Reginster JY: In-vitro differences among nonsteroidal antiinflammatory drugs in their activities related to osteoarthritis pathophysiology. Osteoarthritis Cartilage. 1999, 7: 355-357. 10.1053/joca.1998.0197.CrossRefPubMed
12.
go back to reference Mukherjee P, Rachita C, Aisen PS, Pasinetti GM: Non-steroidal anti-inflammatory drugs protect against chondrocyte apoptotic death. Clin Exp Rheumatol. 2001, 19: S7-S11.PubMed Mukherjee P, Rachita C, Aisen PS, Pasinetti GM: Non-steroidal anti-inflammatory drugs protect against chondrocyte apoptotic death. Clin Exp Rheumatol. 2001, 19: S7-S11.PubMed
13.
go back to reference Fernandes JC, Caron JP, Martel-Pelletier J, Jovanovic D, Mineau F, Tardif G, Otterness IG, Pelletier JP: Effects of tenidap on the progression of osteoarthritic lesions in a canine experimental model. Suppression of metalloprotease and interleukin-1 activity. Arthritis Rheum. 1997, 40: 284-294.CrossRefPubMed Fernandes JC, Caron JP, Martel-Pelletier J, Jovanovic D, Mineau F, Tardif G, Otterness IG, Pelletier JP: Effects of tenidap on the progression of osteoarthritic lesions in a canine experimental model. Suppression of metalloprotease and interleukin-1 activity. Arthritis Rheum. 1997, 40: 284-294.CrossRefPubMed
14.
go back to reference Pelletier JP, Lajeunesse D, Jovanovic DV, Lascau-Coman V, Jolicoeur FC, Hilal G, Fernandes JC, Martel-Pelletier J: Carprofen simultaneously reduces progression of morphological changes in cartilage and subchondral bone in experimental dog osteoarthritis. J Rheumatol. 2000, 27: 2893-2902.PubMed Pelletier JP, Lajeunesse D, Jovanovic DV, Lascau-Coman V, Jolicoeur FC, Hilal G, Fernandes JC, Martel-Pelletier J: Carprofen simultaneously reduces progression of morphological changes in cartilage and subchondral bone in experimental dog osteoarthritis. J Rheumatol. 2000, 27: 2893-2902.PubMed
15.
go back to reference Ratcliffe A, Azzo W, Saed-Nejad F, Lane N, Rosenwasser MP, Mow VC: In vivo effects of naproxen on composition, proteoglycan metabolism, and matrix metalloproteinase activities in canine articular cartilage. J Orthop Res. 1993, 11: 163-171. 10.1002/jor.1100110203.CrossRefPubMed Ratcliffe A, Azzo W, Saed-Nejad F, Lane N, Rosenwasser MP, Mow VC: In vivo effects of naproxen on composition, proteoglycan metabolism, and matrix metalloproteinase activities in canine articular cartilage. J Orthop Res. 1993, 11: 163-171. 10.1002/jor.1100110203.CrossRefPubMed
16.
go back to reference Serni U, Mannoni A, Benucci M: Is there preliminary in-vivo evidence for an influence of nonsteroidal antiinflammatory drugs on progression in osteoarthritis? Part II-evidence from animal models. Osteoarthritis Cartilage. 1999, 7: 351-352. 10.1053/joca.1998.0195.CrossRefPubMed Serni U, Mannoni A, Benucci M: Is there preliminary in-vivo evidence for an influence of nonsteroidal antiinflammatory drugs on progression in osteoarthritis? Part II-evidence from animal models. Osteoarthritis Cartilage. 1999, 7: 351-352. 10.1053/joca.1998.0195.CrossRefPubMed
17.
go back to reference Mastbergen SC, Lafeber FP, Bijlsma JW: Selective COX-2 inhibition prevents proinflammatory cytokine-induced cartilage damage. Rheumatology (Oxford). 2002, 41: 801-808. 10.1093/rheumatology/41.7.801.CrossRef Mastbergen SC, Lafeber FP, Bijlsma JW: Selective COX-2 inhibition prevents proinflammatory cytokine-induced cartilage damage. Rheumatology (Oxford). 2002, 41: 801-808. 10.1093/rheumatology/41.7.801.CrossRef
18.
go back to reference El Hajjaji H, Marcelis A, Devogelaer JP, Manicourt DH: Celecoxib has a positive effect on the overall metabolism of hyaluronan and proteoglycans in human osteoarthritic cartilage. J Rheumatol. 2003, 30: 2444-2451.PubMed El Hajjaji H, Marcelis A, Devogelaer JP, Manicourt DH: Celecoxib has a positive effect on the overall metabolism of hyaluronan and proteoglycans in human osteoarthritic cartilage. J Rheumatol. 2003, 30: 2444-2451.PubMed
19.
go back to reference Mastbergen SC, Bijlsma JW, Lafeber FP: Selective COX-2 inhibition is favorable to human early and late-stage osteoarthritic cartilage: a human in vitro study. Osteoarthritis Cartilage. 2005, 13: 519-526. 10.1016/j.joca.2005.02.004.CrossRefPubMed Mastbergen SC, Bijlsma JW, Lafeber FP: Selective COX-2 inhibition is favorable to human early and late-stage osteoarthritic cartilage: a human in vitro study. Osteoarthritis Cartilage. 2005, 13: 519-526. 10.1016/j.joca.2005.02.004.CrossRefPubMed
20.
go back to reference Warner TD, Mitchell JA: Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J. 2004, 18: 790-804. 10.1096/fj.03-0645rev.CrossRefPubMed Warner TD, Mitchell JA: Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J. 2004, 18: 790-804. 10.1096/fj.03-0645rev.CrossRefPubMed
21.
go back to reference Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR: Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA. 1999, 96: 7563-7568. 10.1073/pnas.96.13.7563.PubMedCentralCrossRefPubMed Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR: Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA. 1999, 96: 7563-7568. 10.1073/pnas.96.13.7563.PubMedCentralCrossRefPubMed
22.
go back to reference Lafeber FP, Vander Kraan PM, Huber-Bruning O, Vanden Berg WB, Bijlsma JW: Osteoarthritic human cartilage is more sensitive to transforming growth factor beta than is normal cartilage. Br J Rheumatol. 1993, 32: 281-286.CrossRefPubMed Lafeber FP, Vander Kraan PM, Huber-Bruning O, Vanden Berg WB, Bijlsma JW: Osteoarthritic human cartilage is more sensitive to transforming growth factor beta than is normal cartilage. Br J Rheumatol. 1993, 32: 281-286.CrossRefPubMed
23.
go back to reference Lafeber FP, van der Kraan PM, van Roy HL, Vitters EL, Huber-Bruning O, van den Berg WB, Bijlsma JW: Local changes in proteoglycan synthesis during culture are different for normal and osteoarthritic cartilage. Am J Pathol. 1992, 140: 1421-1429.PubMedCentralPubMed Lafeber FP, van der Kraan PM, van Roy HL, Vitters EL, Huber-Bruning O, van den Berg WB, Bijlsma JW: Local changes in proteoglycan synthesis during culture are different for normal and osteoarthritic cartilage. Am J Pathol. 1992, 140: 1421-1429.PubMedCentralPubMed
24.
go back to reference Mankin HJ, Dorfman H, Lippiello L, Zarins A: Biochemical and metabolic abnormalities in articular cartilage from osteo-arthritic human hips. II. Correlation of morphology with biochemical and metabolic data. J Bone Joint Surg Am. 1971, 53: 523-537.PubMed Mankin HJ, Dorfman H, Lippiello L, Zarins A: Biochemical and metabolic abnormalities in articular cartilage from osteo-arthritic human hips. II. Correlation of morphology with biochemical and metabolic data. J Bone Joint Surg Am. 1971, 53: 523-537.PubMed
25.
go back to reference Bort R, Ponsoda X, Carrasco E, Gomez-Lechon MJ, Castell JV: Metabolism of aceclofenac in humans. Drug Metab Dispos. 1996, 24: 834-841.PubMed Bort R, Ponsoda X, Carrasco E, Gomez-Lechon MJ, Castell JV: Metabolism of aceclofenac in humans. Drug Metab Dispos. 1996, 24: 834-841.PubMed
26.
go back to reference Paulson SK, Hribar JD, Liu NW, Hajdu E, Bible RH, Piergies A, Karim A: Metabolism and excretion of [14C]celecoxib in healthy male volunteers. Drug Metab Dispos. 2000, 28: 308-314.PubMed Paulson SK, Hribar JD, Liu NW, Hajdu E, Bible RH, Piergies A, Karim A: Metabolism and excretion of [14C]celecoxib in healthy male volunteers. Drug Metab Dispos. 2000, 28: 308-314.PubMed
27.
go back to reference Schulz M, Schmoldt A: Therapeutic and toxic blood concentrations of more than 800 drugs and other xenobiotics. Pharmazie. 2003, 58: 447-474.PubMed Schulz M, Schmoldt A: Therapeutic and toxic blood concentrations of more than 800 drugs and other xenobiotics. Pharmazie. 2003, 58: 447-474.PubMed
28.
go back to reference Lafeber FP, Vander Kraan PM, Van Roy JL, Huber-Bruning O, Bijlsma JW: Articular cartilage explant culture; an appropriate in vitro system to compare osteoarthritic and normal human cartilage. Connect Tissue Res. 1993, 29: 287-299.CrossRefPubMed Lafeber FP, Vander Kraan PM, Van Roy JL, Huber-Bruning O, Bijlsma JW: Articular cartilage explant culture; an appropriate in vitro system to compare osteoarthritic and normal human cartilage. Connect Tissue Res. 1993, 29: 287-299.CrossRefPubMed
30.
go back to reference Curry SL, Cogar SM, Cook JL: Nonsteroidal antiinflammatory drugs: a review. J Am Anim Hosp Assoc. 2005, 41: 298-309.CrossRefPubMed Curry SL, Cogar SM, Cook JL: Nonsteroidal antiinflammatory drugs: a review. J Am Anim Hosp Assoc. 2005, 41: 298-309.CrossRefPubMed
31.
go back to reference Collier S, Ghosh P: Comparison of the effects of non-steroidal anti-inflammatory drugs (NSAIDs) on proteoglycan synthesis by articular cartilage explant and chondrocyte monolayer cultures. Biochem Pharmacol. 1991, 41: 1375-1384. 10.1016/0006-2952(91)90111-H.CrossRefPubMed Collier S, Ghosh P: Comparison of the effects of non-steroidal anti-inflammatory drugs (NSAIDs) on proteoglycan synthesis by articular cartilage explant and chondrocyte monolayer cultures. Biochem Pharmacol. 1991, 41: 1375-1384. 10.1016/0006-2952(91)90111-H.CrossRefPubMed
32.
go back to reference Smith RL, Kajiyama G, Lane NE: Nonsteroidal antiinflammatory drugs: effects on normal and interleukin 1 treated human articular chondrocyte metabolism in vitro. J Rheumatol. 1995, 22: 1130-1137.PubMed Smith RL, Kajiyama G, Lane NE: Nonsteroidal antiinflammatory drugs: effects on normal and interleukin 1 treated human articular chondrocyte metabolism in vitro. J Rheumatol. 1995, 22: 1130-1137.PubMed
33.
go back to reference David MJ, Vignon E, Peschard MJ, Broquet P, Louisot P, Richard M: Effect of non-steroidal anti-inflammatory drugs (NSAIDS) on glycosyltransferase activity from human osteoarthritic cartilage. Br J Rheumatol. 1992, 31 Suppl 1: 13-17.PubMed David MJ, Vignon E, Peschard MJ, Broquet P, Louisot P, Richard M: Effect of non-steroidal anti-inflammatory drugs (NSAIDS) on glycosyltransferase activity from human osteoarthritic cartilage. Br J Rheumatol. 1992, 31 Suppl 1: 13-17.PubMed
34.
go back to reference Bort R, Ponsoda X, Carrasco E, Gomez-Lechon MJ, Castell JV: Comparative metabolism of the nonsteroidal antiinflammatory drug, aceclofenac, in the rat, monkey, and human. Drug Metab Dispos. 1996, 24: 969-975.PubMed Bort R, Ponsoda X, Carrasco E, Gomez-Lechon MJ, Castell JV: Comparative metabolism of the nonsteroidal antiinflammatory drug, aceclofenac, in the rat, monkey, and human. Drug Metab Dispos. 1996, 24: 969-975.PubMed
35.
go back to reference Henrotin Y, de Leval X, Mathy-Hartet M, Mouithys-Mickalad A, Deby-Dupont G, Dogne JM, Delarge J, Reginster JY: In vitro effects of aceclofenac and its metabolites on the production by chondrocytes of inflammatory mediators. Inflamm Res. 2001, 50: 391-399. 10.1007/PL00000261.CrossRefPubMed Henrotin Y, de Leval X, Mathy-Hartet M, Mouithys-Mickalad A, Deby-Dupont G, Dogne JM, Delarge J, Reginster JY: In vitro effects of aceclofenac and its metabolites on the production by chondrocytes of inflammatory mediators. Inflamm Res. 2001, 50: 391-399. 10.1007/PL00000261.CrossRefPubMed
36.
go back to reference Hinz B, Rau T, Auge D, Werner U, Ramer R, Rietbrock S, Brune K: Aceclofenac spares cyclooxygenase 1 as a result of limited but sustained biotransformation to diclofenac. Clin Pharmacol Ther. 2003, 74: 222-235. 10.1016/S0009-9236(03)00167-X.CrossRefPubMed Hinz B, Rau T, Auge D, Werner U, Ramer R, Rietbrock S, Brune K: Aceclofenac spares cyclooxygenase 1 as a result of limited but sustained biotransformation to diclofenac. Clin Pharmacol Ther. 2003, 74: 222-235. 10.1016/S0009-9236(03)00167-X.CrossRefPubMed
37.
go back to reference Yamazaki R, Kawai S, Matsuzaki T, Kaneda N, Hashimoto S, Yokokura T, Okamoto R, Koshino T, Mizushima Y: Aceclofenac blocks prostaglandin E2 production following its intracellular conversion into cyclooxygenase inhibitors. Eur J Pharmacol. 1997, 329: 181-187.CrossRefPubMed Yamazaki R, Kawai S, Matsuzaki T, Kaneda N, Hashimoto S, Yokokura T, Okamoto R, Koshino T, Mizushima Y: Aceclofenac blocks prostaglandin E2 production following its intracellular conversion into cyclooxygenase inhibitors. Eur J Pharmacol. 1997, 329: 181-187.CrossRefPubMed
38.
go back to reference Vane JR, Botting RM: Mechanism of action of nonsteroidal anti-inflammatory drugs. Am J Med. 1998, 104: 2S-8S. 10.1016/S0002-9343(97)00203-9.CrossRefPubMed Vane JR, Botting RM: Mechanism of action of nonsteroidal anti-inflammatory drugs. Am J Med. 1998, 104: 2S-8S. 10.1016/S0002-9343(97)00203-9.CrossRefPubMed
39.
go back to reference Knorth H, Dorfmuller P, Lebert R, Schmidt WE, Wittenberg RH, Heukamp M, Wiese M, Willburger RE: Participation of cyclooxygenase-1 in prostaglandin E2 release from synovitis tissue in primary osteoarthritis in vitro. Osteoarthritis Cartilage. 2004, 12: 658-666. 10.1016/j.joca.2004.05.002.CrossRefPubMed Knorth H, Dorfmuller P, Lebert R, Schmidt WE, Wittenberg RH, Heukamp M, Wiese M, Willburger RE: Participation of cyclooxygenase-1 in prostaglandin E2 release from synovitis tissue in primary osteoarthritis in vitro. Osteoarthritis Cartilage. 2004, 12: 658-666. 10.1016/j.joca.2004.05.002.CrossRefPubMed
40.
go back to reference Loftin CD, Tiano HF, Langenbach R: Phenotypes of the COX-deficient mice indicate physiological and pathophysiological roles for COX-1 and COX-2. Prostaglandins Other Lipid Mediat. 2002, 68-69: 177-185. 10.1016/S0090-6980(02)00028-X.CrossRefPubMed Loftin CD, Tiano HF, Langenbach R: Phenotypes of the COX-deficient mice indicate physiological and pathophysiological roles for COX-1 and COX-2. Prostaglandins Other Lipid Mediat. 2002, 68-69: 177-185. 10.1016/S0090-6980(02)00028-X.CrossRefPubMed
41.
go back to reference Martinez RV, Reval M, Campos MD, Terron JA, Dominguez R, Lopez-Munoz FJ: Involvement of peripheral cyclooxygenase-1 and cyclooxygenase-2 in inflammatory pain. J Pharm Pharmacol. 2002, 54: 405-412. 10.1211/0022357021778475.CrossRefPubMed Martinez RV, Reval M, Campos MD, Terron JA, Dominguez R, Lopez-Munoz FJ: Involvement of peripheral cyclooxygenase-1 and cyclooxygenase-2 in inflammatory pain. J Pharm Pharmacol. 2002, 54: 405-412. 10.1211/0022357021778475.CrossRefPubMed
42.
go back to reference Hardy MM, Seibert K, Manning PT, Currie MG, Woerner BM, Edwards D, Koki A, Tripp CS: Cyclooxygenase 2-dependent prostaglandin E2 modulates cartilage proteoglycan degradation in human osteoarthritis explants. Arthritis Rheum. 2002, 46: 1789-1803. 10.1002/art.10356.CrossRefPubMed Hardy MM, Seibert K, Manning PT, Currie MG, Woerner BM, Edwards D, Koki A, Tripp CS: Cyclooxygenase 2-dependent prostaglandin E2 modulates cartilage proteoglycan degradation in human osteoarthritis explants. Arthritis Rheum. 2002, 46: 1789-1803. 10.1002/art.10356.CrossRefPubMed
43.
go back to reference Morita I: Distinct functions of COX-1 and COX-2. Prostaglandins Other Lipid Mediat. 2002, 68-69: 165-175. 10.1016/S0090-6980(02)00029-1.CrossRefPubMed Morita I: Distinct functions of COX-1 and COX-2. Prostaglandins Other Lipid Mediat. 2002, 68-69: 165-175. 10.1016/S0090-6980(02)00029-1.CrossRefPubMed
44.
go back to reference Tegeder I, Pfeilschifter J, Geisslinger G: Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J. 2001, 15: 2057-2072. 10.1096/fj.01-0390rev.CrossRefPubMed Tegeder I, Pfeilschifter J, Geisslinger G: Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J. 2001, 15: 2057-2072. 10.1096/fj.01-0390rev.CrossRefPubMed
45.
go back to reference McCracken JD, Wechter WJ, Liu Y, Chase RL, Kantoci D, Murray ED, Quiggle DD, Mineyama Y: Antiproliferative effects of the enantiomers of flurbiprofen. J Clin Pharmacol. 1996, 36: 540-545.CrossRefPubMed McCracken JD, Wechter WJ, Liu Y, Chase RL, Kantoci D, Murray ED, Quiggle DD, Mineyama Y: Antiproliferative effects of the enantiomers of flurbiprofen. J Clin Pharmacol. 1996, 36: 540-545.CrossRefPubMed
46.
go back to reference Shiff SJ, Qiao L, Tsai LL, Rigas B: Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells. J Clin Invest. 1995, 96: 491-503.PubMedCentralCrossRefPubMed Shiff SJ, Qiao L, Tsai LL, Rigas B: Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells. J Clin Invest. 1995, 96: 491-503.PubMedCentralCrossRefPubMed
47.
go back to reference Zhang X, Morham SG, Langenbach R, Young DA: Malignant transformation and antineoplastic actions of nonsteroidal antiinflammatory drugs (NSAIDs) on cyclooxygenase-null embryo fibroblasts. J Exp Med. 1999, 190: 451-459. 10.1084/jem.190.4.451.PubMedCentralCrossRefPubMed Zhang X, Morham SG, Langenbach R, Young DA: Malignant transformation and antineoplastic actions of nonsteroidal antiinflammatory drugs (NSAIDs) on cyclooxygenase-null embryo fibroblasts. J Exp Med. 1999, 190: 451-459. 10.1084/jem.190.4.451.PubMedCentralCrossRefPubMed
48.
go back to reference Cronstein BN, Montesinos MC, Weissmann G: Salicylates and sulfasalazine, but not glucocorticoids, inhibit leukocyte accumulation by an adenosine-dependent mechanism that is independent of inhibition of prostaglandin synthesis and p105 of NFkappaB. Proc Natl Acad Sci USA. 1999, 96: 6377-6381. 10.1073/pnas.96.11.6377.PubMedCentralCrossRefPubMed Cronstein BN, Montesinos MC, Weissmann G: Salicylates and sulfasalazine, but not glucocorticoids, inhibit leukocyte accumulation by an adenosine-dependent mechanism that is independent of inhibition of prostaglandin synthesis and p105 of NFkappaB. Proc Natl Acad Sci USA. 1999, 96: 6377-6381. 10.1073/pnas.96.11.6377.PubMedCentralCrossRefPubMed
49.
go back to reference Oeth P, Mackman N: Salicylates inhibit lipopolysaccharide-induced transcriptional activation of the tissue factor gene in human monocytic cells. Blood. 1995, 86: 4144-4152.PubMed Oeth P, Mackman N: Salicylates inhibit lipopolysaccharide-induced transcriptional activation of the tissue factor gene in human monocytic cells. Blood. 1995, 86: 4144-4152.PubMed
50.
go back to reference Pierce JW, Read MA, Ding H, Luscinskas FW, Collins T: Salicylates inhibit I kappa B-alpha phosphorylation, endothelial-leukocyte adhesion molecule expression, and neutrophil transmigration. J Immunol. 1996, 156: 3961-3969.PubMed Pierce JW, Read MA, Ding H, Luscinskas FW, Collins T: Salicylates inhibit I kappa B-alpha phosphorylation, endothelial-leukocyte adhesion molecule expression, and neutrophil transmigration. J Immunol. 1996, 156: 3961-3969.PubMed
51.
go back to reference Huang C, Ma WY, Hanenberger D, Cleary MP, Bowden GT, Dong Z: Inhibition of ultraviolet B-induced activator protein-1 (AP-1) activity by aspirin in AP-1-luciferase transgenic mice. J Biol Chem. 1997, 272: 26325-26331. 10.1074/jbc.272.42.26325.CrossRefPubMed Huang C, Ma WY, Hanenberger D, Cleary MP, Bowden GT, Dong Z: Inhibition of ultraviolet B-induced activator protein-1 (AP-1) activity by aspirin in AP-1-luciferase transgenic mice. J Biol Chem. 1997, 272: 26325-26331. 10.1074/jbc.272.42.26325.CrossRefPubMed
52.
go back to reference Weber C, Erl W, Pietsch A, Weber PC: Aspirin inhibits nuclear factor-kappa B mobilization and monocyte adhesion in stimulated human endothelial cells. Circulation. 1995, 91: 1914-1917.CrossRefPubMed Weber C, Erl W, Pietsch A, Weber PC: Aspirin inhibits nuclear factor-kappa B mobilization and monocyte adhesion in stimulated human endothelial cells. Circulation. 1995, 91: 1914-1917.CrossRefPubMed
53.
go back to reference Yamamoto Y, Yin MJ, Lin KM, Gaynor RB: Sulindac inhibits activation of the NF-kappaB pathway. J Biol Chem. 1999, 274: 27307-27314. 10.1074/jbc.274.38.27307.CrossRefPubMed Yamamoto Y, Yin MJ, Lin KM, Gaynor RB: Sulindac inhibits activation of the NF-kappaB pathway. J Biol Chem. 1999, 274: 27307-27314. 10.1074/jbc.274.38.27307.CrossRefPubMed
54.
go back to reference Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SA: Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem. 1997, 272: 3406-3410. 10.1074/jbc.272.6.3406.CrossRefPubMed Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SA: Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem. 1997, 272: 3406-3410. 10.1074/jbc.272.6.3406.CrossRefPubMed
55.
go back to reference Takada Y, Bhardwaj A, Potdar P, Aggarwal BB: Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-kappaB activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation. Oncogene. 2004, 23: 9247-9258.PubMed Takada Y, Bhardwaj A, Potdar P, Aggarwal BB: Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-kappaB activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation. Oncogene. 2004, 23: 9247-9258.PubMed
56.
go back to reference Sylvester J, Liacini A, Li WQ, Zafarullah M: Interleukin-17 signal transduction pathways implicated in inducing matrix metalloproteinase-3, -13 and aggrecanase-1 genes in articular chondrocytes. Cell Signal. 2004, 16: 469-476. 10.1016/j.cellsig.2003.09.008.CrossRefPubMed Sylvester J, Liacini A, Li WQ, Zafarullah M: Interleukin-17 signal transduction pathways implicated in inducing matrix metalloproteinase-3, -13 and aggrecanase-1 genes in articular chondrocytes. Cell Signal. 2004, 16: 469-476. 10.1016/j.cellsig.2003.09.008.CrossRefPubMed
Metadata
Title
Differential direct effects of cyclo-oxygenase-1/2 inhibition on proteoglycan turnover of human osteoarthritic cartilage: an in vitrostudy
Authors
Simon C Mastbergen
Nathalie WD Jansen
Johannes WJ Bijlsma
Floris PJG Lafeber
Publication date
01-02-2005
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 1/2006
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar1846

Other articles of this Issue 1/2006

Arthritis Research & Therapy 1/2006 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.